- Tytuł:
-
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase ina 2-week on, 2-week off schedule in patients with advanced solid tumours. - Autorzy:
- Źródło:
- British journal of cancer [Br J Cancer] 2008 Jan 15; Vol. 98 (1), pp. 80-5. Date of Electronic Publication: 2007 Nov 20.
- Typ publikacji:
- Clinical Trial, Phase I; Journal Article
- MeSH Terms:
-
ErbB Receptors/*antagonists & inhibitors
Neoplasms/*drug therapy
Quinazolines/*administration & dosage
Receptor, ErbB-2/*antagonists & inhibitors
Adolescent ; Adult ; Afatinib ; Aged ; Aged, 80 and over ; Dose-Response Relationship, Drug ; Female ; Humans ; Keratinocytes/cytology ; Keratinocytes/drug effects ; Keratinocytes/metabolism ; Male ; Maximum Tolerated Dose ; Middle Aged ; Quinazolines/adverse effects ; Quinazolines/pharmacokinetics ; Skin/cytology ; Skin/drug effects ; Skin/metabolism ; Time Factors ; Tissue Distribution ; Treatment Outcome
Czasopismo naukowe